News | Ultrasound Women's Health | September 08, 2017

Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project

Study data will compare ultrasound with mammography to support SoftVue FDA submission for breast cancer supplemental screening indication

Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project

September 8, 2017 — Delphinus Medical Technologies Inc. announced that the SoftVue Discover Breast Ultrasound Prospective Case Collection project has launched, enrolling the first patient. Qualified participants will undergo screening digital mammography as well as SoftVue 3D whole breast ultrasound exams. Information gathered from the project will compare SoftVue imaging to digital mammography to determine the effectiveness of detecting additional cancers with SoftVue that are not seen with mammography alone, particularly in women with dense breast tissue.

The project will enroll 10,000 asymptomatic women with dense breast tissue at several centers in the United States. More than 40 percent1 of women nationwide have dense breast tissue, which is unrelated to weight or breast size. Because dense breasts can mask potential cancers on mammography, the sensitivity for detecting breast cancer is lower in women with dense breasts. Studies have shown that in dense breasts, ultrasound can detect cancers not seen on mammography. However, traditional handheld ultrasound exams can be time-consuming and often operator-dependent. They also have a high rate of false positives, resulting in unnecessary biopsies and added cost to the healthcare system.

In contrast, SoftVue is a fast, fully automated and gentle system that conducts scans while a woman lies on her stomach on a padded table, with her breast supported in a warm water bath. A 360-degree ring transducer images the entire breast in a single pass, moving from the front of the breast to the chest wall. The entire scan takes about two to four minutes per breast, and there is no radiation exposure or compression of the breast. Unlike handheld ultrasound, SoftVue can provide multiple distinctive tissue qualities to radiologists, allowing them to differentiate possible cancers from normal to benign findings.

“Dense breast tissue can mask or hide cancer, making it more difficult for mammography to detect cancer. And while ultrasound has been shown to be effective in detecting cancer in dense breasts, there’s a need for advanced technology like SoftVue that enables fast and comfortable whole breast ultrasound with fewer false positives," said Mary Yamashita, M.D., assistant professor of clinical radiology at the University of Southern California (USC) Norris Comprehensive Cancer Center and the national principal investigator of the Discover Breast Ultrasound project. “This important research will help us confirm the efficacy of the SoftVue system and potentially help establish new standards of care in dense breast tissue cancer screening.”

The Discover Breast Ultrasound project is recruiting participants at centers that include:

  • USC Norris Comprehensive Cancer Center;
  • Mt. Sinai Medical Center;
  • Beaumont Hospital - Dearborn;
  • Elizabeth Wende Breast Care;
  • Southcoast Health Imaging;
  • St. Elizabeth Hospital, part of Ascension; and
  • Weinstein Imaging.

Data from this study will support the company’s submission of a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for a supplemental screening indication for women with dense breasts in combination with mammography. SoftVue has already received two 510(k) clearances from the FDA for diagnostic breast ultrasound imaging and is not intended for use as a replacement for screening mammography. The technology is currently only in use at participating sites.

For more information: www.discoversoftvue.com

 

References

1. Sprague BL, et al. Prevalence of Mammographically Dense Breasts in the United States. J Natl Cancer Inst. 2014 Oct; 106(10): dju255. Published online 2014 Sep 12.

Related Content

Sponsored Content | Videos | Pediatric Imaging | February 22, 2018
FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM SonoSite Inc., are offering a full-suite pediatric solutions...
Sponsored Content | Videos | Flat Panel Displays | February 21, 2018
This 5 megapixel, high-brightness color monitor has the high-definition display necessary for breast imaging.
Barco Highlights Imaging Workflow Compliance at HIMSS18
News | Flat Panel Displays | February 21, 2018
Barco will showcase its full line of radiology and mammography display systems with online quality assurance (QA)...
DenseBreast-info.org Launches European-Focused Education Coalition
News | Breast Density | February 19, 2018
DenseBreast-info.org (DB-I) announced plans for international expansion with specialized content for Europe and...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Sponsored Content | Videos | Imaging | February 15, 2018
David Widmann, president and CEO of Konica Minolta, looks at what the future of healthcare can bring to its customers,...
Sponsored Content | Videos | Artificial Intelligence | February 15, 2018
ITN Contributing Editor Greg Freiherr offers an overview of artificial intelligence advances at the Radiological Soci
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Videos | Enterprise Imaging | February 13, 2018
ITN Contributing Editor Greg Freiherr offers an overview of enterprise imaging advances at the Radiological Society of...
Overlay Init